Biotechnology Patent Litigation In Russia.

1. Introduction

Biotechnology patent litigation in Russia concerns legal disputes arising from the ownership, validity, infringement, licensing, commercialization and enforcement of patents relating to biological inventions. These inventions include genetically modified organisms (GMOs), gene-editing technologies, pharmaceutical biotechnology, vaccines, antibodies, recombinant proteins, DNA sequences, diagnostic methods, stem-cell technologies and industrial biological processes.

Russia's biotechnology patent litigation framework is primarily governed by Part IV of the Civil Code of the Russian Federation, which establishes intellectual property rights and regulates patent protection.

The principal objective of Russian patent litigation is to balance three interests:

Protecting inventors and biotechnology companies against unauthorized exploitation of their inventions.

Ensuring that patents satisfy legal requirements, including novelty, inventive step and industrial applicability.

Protecting public health, scientific research, competition and access to essential medicines.

Biotechnology disputes are particularly complex because courts must examine both technical scientific evidence and legal questions concerning patentability, claim interpretation, infringement and the scope of exclusive rights.

2. Legal framework governing biotechnology patent litigation

The following laws and provisions are particularly important.

Legal authorityApplication to biotechnology disputes
Russian Civil Code, Part IVMain legislation governing patent rights
Article 1349Subject matter excluded from patent protection
Article 1350Patentability requirements
Article 1353State registration of patents
Article 1354Scope of patent protection
Article 1356Inventorship
Article 1357Right to obtain a patent
Article 1358Exclusive rights and infringement
Article 1362Compulsory licensing
Article 1387Granting or refusing patents
Article 1398Invalidity of patents
Article 1406Patent-related disputes
Arbitration Procedure CodeJudicial proceedings in commercial disputes

A. Patentability of biotechnology inventions

Article 1350 establishes three principal requirements for patentability:

Novelty: The invention must not already form part of the prior art.

Inventive step: The invention must not be obvious to a person skilled in the relevant technical field.

Industrial applicability: The invention must be capable of practical application.

For biotechnology, these requirements raise difficult questions.

For example, a company applying for a patent over a genetically engineered microorganism must establish that its claimed invention is sufficiently distinguishable from previously disclosed organisms or genetic modifications.

A patent application involving an isolated biological substance must also explain the technical contribution and its practical applicability.

B. Excluded biotechnology inventions

Russian law imposes specific restrictions on patentable subject matter.

Article 1349 excludes, among other things:

Human cloning processes and human clones.

Methods of modifying the genetic integrity of human embryo cells.

Use of human embryos for industrial and commercial purposes.

Certain inventions contrary to public interest, humanitarian principles and morality.

These exclusions are important when disputes concern embryo research, reproductive biotechnology, human genetic engineering and cloning technologies.

C. Exclusive rights and patent infringement

Under Article 1358, a patent holder has the exclusive right to exploit a patented invention within the legally protected scope.

Unauthorized exploitation may include:

Manufacturing a patented biological product.

Using a patented genetic-engineering process.

Importing a patented biotechnology product.

Selling or commercially distributing a patented pharmaceutical composition.

Using a protected microorganism or biological production method.

Article 1354 makes the patent claims central to determining the scope of protection. Therefore, a biotechnology infringement case generally requires a comparison between the patent claims and the allegedly infringing product or process.

rospatent.gov.ru+1

3. Institutions responsible for biotechnology patent disputes

1. Rospatent

Rospatent administers the Russian patent registration system. Its responsibilities include:

Examination of patent applications.

Registration of inventions.

Granting patents.

Administrative consideration of certain patent challenges.

Maintaining patent registers.

2. Chamber for Patent Disputes

The Chamber for Patent Disputes operates within the Rospatent administrative framework. It considers objections relating to patent grants and patent validity.

A biotechnology company may challenge a competitor's patent on grounds such as lack of novelty, insufficient inventive contribution or failure to satisfy statutory patentability conditions.

3. Court for Intellectual Property Rights

The Court for Intellectual Property Rights (IP Court) has a specialised role in Russian intellectual property litigation.

It examines certain intellectual property disputes as a court of first instance, particularly challenges to decisions of Rospatent, and acts as a cassation court in qualifying intellectual property cases.

4. Commercial arbitration courts

Commercial patent infringement proceedings are generally handled by the Russian state commercial courts (arbitrazh courts).

They determine questions involving patent infringement, damages, compulsory licences and other commercial intellectual property claims.

4. Major categories of biotechnology patent litigation

A. Pharmaceutical biotechnology patent infringement

This category includes disputes involving patented biological medicines, recombinant proteins, vaccines, antibodies and pharmaceutical formulations.

For example, a biotechnology company may develop a biosimilar medicine using a biological substance protected by another company's patent.

The patent holder may allege that the biosimilar manufacturer has reproduced a protected invention without authorization.

The court must examine:

The scope of the patent claims.

The technical characteristics of the accused product.

Whether all legally relevant claim features are present.

Whether the defendant has a valid licence or other statutory defence.

The availability of appropriate remedies.

B. Genetic engineering patent disputes

These disputes may involve patented DNA constructs, genetically modified microorganisms, gene-editing techniques and recombinant production systems.

The principal legal difficulty is determining whether the accused genetic material or production process falls within the patent claims.

Scientific experts may be required to analyse genetic sequences, molecular structures, laboratory procedures and technical descriptions.

C. Patent ownership and inventorship disputes

Biotechnology inventions frequently arise from collaborative research involving universities, hospitals, laboratories, researchers and pharmaceutical companies.

Disputes may arise where:

A researcher claims to have been omitted as an inventor.

A company claims ownership of an employee-created invention.

A university disputes the transfer of patent rights.

A biotechnology start-up alleges that a former employee improperly transferred confidential technical information.

Article 1356 protects the right of inventorship, while Article 1357 regulates the right to obtain a patent.

D. Patent invalidity litigation

A biotechnology patent may be challenged if it fails to satisfy the statutory patentability requirements.

Common grounds include:

Lack of novelty.

Lack of inventive step.

Lack of industrial applicability.

Inadequate disclosure of the invention.

Failure to satisfy statutory restrictions on patentable subject matter.

Article 1398 is particularly important because it provides grounds for invalidating patents.

E. Compulsory licensing disputes

Article 1362 provides mechanisms for compulsory licensing in specified circumstances.

These disputes are particularly important in pharmaceutical biotechnology because patent exclusivity may conflict with public-health requirements and access to medicines.

A court must examine the applicable statutory conditions rather than assume that public-health importance automatically authorizes unauthorized use of a patented invention.

5. Important Russian case laws concerning biotechnology patent litigation

Russia does not have a large body of reported judgments exclusively devoted to biotechnology patent infringement. However, pharmaceutical biotechnology disputes provide important judicial guidance on patent exclusivity, dependent inventions, compulsory licensing and scientific evidence.

The following cases are particularly relevant.

Case 1: Nativa LLC v. Celgene Corporation – Lenalidomide patent dispute (2017–2019)

Important compulsory licensing precedent

Case number: A40-71471/2017

Court: Moscow Arbitration Court; subsequently reviewed by the Intellectual Property Court.

Subject: Patent rights concerning lenalidomide, a medicine used in the treatment of multiple myeloma.

Relevant legislation: Articles 1358 and 1362 of the Civil Code.

Facts of the case

Celgene Corporation held Russian patent protection for lenalidomide. Nativa sought to manufacture and commercialize a corresponding medicine.

Nativa relied on a separate patent concerning a crystalline modification of lenalidomide. It argued that its patented invention was dependent on Celgene's earlier invention and that its own invention offered significant technical and economic advantages.

The company sought a compulsory non-exclusive licence.

Judicial decision

On 8 June 2018, the Moscow Arbitration Court granted the compulsory licence. The royalty was fixed at 30% of the specified income base, calculated after VAT and direct material expenses.

However, the litigation did not end with that decision. On 27 December 2018, the Intellectual Property Court recorded the parties' settlement and terminated the proceedings, replacing the earlier judicial outcome with the settlement.

The subsequent invalidation of Nativa's relevant patent for lack of inventive step also affected the legal foundation of the dispute.

Legal significance

The case demonstrates:

The importance of dependent inventions in pharmaceutical patent litigation.

The possibility of compulsory licensing under Article 1362.

The need to establish technical and economic advantages.

The relationship between patent validity and compulsory licensing.

Biotechnology relevance: This dispute is particularly useful for understanding patent conflicts involving biotechnology-derived medicines, although lenalidomide is a pharmaceutical chemical compound rather than a biological drug.

ГАРАНТ+3

Case 2: Sugen LLC and Pharmacia & Upjohn v. Nativa LLC – Sunitinib patent litigation (2017–2020)

Major pharmaceutical patent precedent

Case number: A40-166505/2017

Subject: Patent infringement and compulsory licensing.

Technology: Sunitinib-based pharmaceutical product.

Relevant legislation: Articles 1252, 1358 and 1362 of the Civil Code.

Facts

Sugen LLC and Pharmacia & Upjohn, associated with the Pfizer group, alleged that Nativa's commercialization of Sunitinib-Nativ infringed their patent rights.

Nativa defended its position and sought a compulsory licence through a counterclaim.

The dispute involved the relationship between an earlier patent and a later patent concerning a particular crystalline form of sunitinib.

Judicial outcome

The Moscow Arbitration Court granted Nativa's compulsory-licensing counterclaim.

The decision was subsequently examined by appellate and cassation courts. On 20 February 2020, the Supreme Court refused to transfer the further cassation complaint for consideration by its Judicial Collegium.

The licence terms included a 10% royalty on the specified income base after VAT and direct expenses.

Legal principles

The dispute demonstrates that:

A dependent patent may have important legal consequences.

Patent infringement and compulsory licensing can arise in the same proceedings.

A defendant may seek a compulsory licence where statutory conditions are satisfied.

Courts must examine the technical and economic relationship between competing patented inventions.

Biotechnology relevance: The case is relevant to patent litigation involving pharmaceutical technologies and potentially biotechnology-derived medicines, but it should not be described as a direct gene-editing or recombinant-biotechnology judgment.

Sojuzpatent+2

Case 3: Intellectual Property Court – Pharmaceutical composition patent dispute (SIP-863/2023)

Case number: SIP-863/2023

Decision date: 9 December 2024

Court: Presidium of the Court for Intellectual Property Rights.

Subject: Industrial applicability of pharmaceutical compositions.

Facts

The dispute concerned the validity of a Eurasian patent protecting pharmaceutical compositions.

An objection challenged the industrial applicability of certain independent claims. Rospatent invalidated the patent in its entirety, and the first-instance court upheld that decision.

The matter proceeded to the Presidium of the Intellectual Property Court.

Judicial significance

In its decision, the Presidium addressed the evidentiary requirements for establishing industrial applicability.

The relevant analysis included whether the patent application supplied sufficient technical information demonstrating the composition's suitability for its stated therapeutic purpose.

Evidence concerning ingredients, their characteristics and manufacturing methods was important.

The Presidium also addressed the consequences of invalidating a patent beyond the scope of the objection.

Biotechnology relevance

This judgment is important when litigating patents involving:

Therapeutic proteins.

Biological pharmaceutical compositions.

Recombinant medicines.

Vaccine formulations.

Other biotechnology-derived therapeutic products.

It demonstrates that merely describing a pharmaceutical composition is not necessarily sufficient; the claimed invention must satisfy the applicable patentability requirements.

Liapunov & Reznichenko

Case 4: Russian Government's Remdesivir compulsory-use authorization (2020–2021)

Authority: Government of the Russian Federation.

Instrument: Government Order No. 3718-r of 31 December 2020.

Technology: Remdesivir, an antiviral pharmaceutical product.

Patent holder: Gilead Sciences.

During the COVID-19 pandemic, the Russian Government authorized Pharmasintez to use the relevant invention without the patent holder's consent for a specified period in 2021.

This was an exercise of governmental compulsory-use powers, not an ordinary judicial patent-infringement judgment.

Legal significance

The episode demonstrates the relationship between patent exclusivity, emergency public-health requirements and governmental authorization of patent use.

It is relevant to biotechnology patent disputes involving vaccines, antiviral products and pandemic-related medicines.

Alrud

6. Scientific evidence in biotechnology patent litigation

Scientific evidence is one of the most important aspects of biotechnology patent proceedings.

Unlike ordinary commercial disputes, biotechnology patent litigation often requires detailed technical investigation.

A. Genetic and molecular evidence

Where a patent concerns a DNA sequence, microorganism or genetically engineered product, expert evidence may examine:

DNA and RNA sequences.

Genetic modifications.

Protein structures.

Molecular characteristics.

Biological functionality.

Differences between patented and accused products.

B. Laboratory evidence

Laboratory reports may help establish whether a defendant's manufacturing process uses the patented technology.

Examples include:

PCR analysis.

DNA sequencing.

Protein characterization.

Cell-culture analysis.

Microbiological testing.

Reproducibility studies.

C. Expert witnesses

Courts may rely on independent technical experts to explain scientific questions.

Experts may address:

Whether the accused product contains the patented features.

Whether a claimed biological process has been reproduced.

Whether the patent disclosure is technically sufficient.

Whether the claimed invention is scientifically workable.

Whether prior scientific publications disclose the same invention.

D. Prior-art evidence

Scientific publications, international patent applications, laboratory records, conference proceedings and earlier patent documents can be relevant to novelty and inventive-step challenges.

An important practical issue is preserving the date, authenticity and technical contents of the evidence.

7. Patent infringement proceedings and judicial procedure

Biotechnology patent infringement claims generally proceed through the commercial court system.

Pre-litigation investigation

The patent holder identifies the allegedly infringing biological product, production method or commercial activity.

Filing the infringement claim

The claimant submits the patent documents, evidence of ownership and technical comparison with the allegedly infringing product.

Defendant's response

The defendant may dispute infringement, challenge the patent's validity through the appropriate procedure, or rely on a licence or statutory exception.

Scientific examination

The court may examine technical documents and appoint specialist expertise where necessary.

Judgment

The court determines infringement, liability and the available remedies.

Appeal and cassation

The case may proceed through the competent appellate court, the Intellectual Property Court and, where the statutory conditions are met, the Supreme Court.

An important distinction is that ordinary commercial infringement cases generally begin in a regional arbitrazh court. The Intellectual Property Court does not automatically act as the first-instance court for every patent infringement action.

en.khp.legal

 

8. Remedies available in biotechnology patent litigation

Russian law provides several remedies for the protection of patent rights.

A. Injunctions

Under Article 1252 of the Civil Code, a patent holder may seek judicial measures to stop infringement.

For example, a biotechnology company may request an order preventing a competitor from manufacturing or selling a patented biological medicine without authorization.

B. Compensation and damages

A claimant may seek damages resulting from unauthorized exploitation of its patented invention, subject to the applicable statutory requirements.

The claimant must establish the relevant infringement and satisfy the requirements governing the particular monetary remedy.

C. Seizure and destruction

In appropriate cases, the court may order the seizure or destruction of infringing goods and other measures prescribed by law.

This can be particularly relevant to unauthorized biological pharmaceutical products.

D. Recognition of patent rights

Where ownership or entitlement is disputed, judicial proceedings may establish the relevant legal rights.

E. Compulsory licensing

Article 1362 permits compulsory licensing in specified circumstances, including certain cases involving insufficient use of an invention or dependent inventions.

The circumstances must satisfy the statutory requirements, and the licence conditions must be determined according to the applicable law.

rospatent.gov.ru+1

9. Major challenges in Russian biotechnology patent litigation

Legal challengeExplanation
Scientific complexityCourts must understand complicated biological inventions.
Patent claim interpretationSmall technical differences can affect infringement findings.
Biosimilar disputesDetermining whether a biological medicine uses protected technology can be difficult.
Patent ownershipResearch institutions and commercial companies may claim competing rights.
Genetic informationPatent claims involving genetic material raise questions about statutory exclusions and scope.
Patent validityNovelty, inventive step and industrial applicability can be difficult to establish.
Compulsory licensingPatent exclusivity may conflict with public-health interests.
International enforcementForeign patents do not automatically confer protection in Russia.
ConfidentialityScientific and commercial evidence may contain valuable confidential information.
Research collaborationEmployment and technology-transfer agreements may create ownership disputes.

10. Recent developments in Russian pharmaceutical patent litigation

The Russian pharmaceutical patent market has experienced significant litigation activity.

According to the Association of International Pharmaceutical Manufacturers' analysis covering 2017 to January 2026:

More than 150 intellectual property disputes were identified over the nine-year period.

More than 90 disputes arose during the 2022–2026 period covered by the study.

Compulsory licensing has become an important litigation issue.

Disputes increasingly concern early generic launches and access to pharmaceutical markets.

Questions surrounding the protection of preclinical and clinical trial information have also emerged.

The report highlights continuing uncertainty concerning the interpretation of insufficient use under Article 1362.

These developments are relevant to biotechnology companies developing innovative medicines, biological products and pharmaceutical technologies.

en.aipm.org+1

 

11. International and Eurasian dimensions

Russian biotechnology patent litigation also has an international dimension.

Three legal considerations are particularly important:

1. Eurasian patents

Russia participates in the Eurasian Patent Convention system. A Eurasian patent can provide protection in designated contracting states, subject to the applicable rules.

Disputes involving Eurasian pharmaceutical patents may therefore require consideration of both Eurasian patent rules and Russian judicial procedures.

2. Foreign biotechnology companies

Foreign pharmaceutical and biotechnology companies may enforce qualifying Russian patent rights through Russian legal proceedings.

However, patent protection is territorial. A patent granted in another country does not automatically establish an enforceable Russian patent right.

3. International patent cooperation

International patent applications, scientific publications and foreign patent records may provide relevant prior-art evidence in Russian proceedings.

International agreements and applicable Eurasian rules must also be considered when assessing patent priority, protection and enforcement.

12. Recommendations for biotechnology companies

Companies involved in Russian biotechnology research and commercialization should adopt the following legal safeguards:

Conduct patentability searches before investing in biotechnology research.

Maintain detailed laboratory records and research documentation.

Establish clear ownership arrangements with scientists and research institutions.

Prepare technically detailed patent claims.

Preserve evidence of novelty and inventive contribution.

Conduct patent infringement searches before commercializing biological products.

Review licensing agreements and technology-transfer arrangements.

Monitor competing Russian and Eurasian patents.

Preserve scientific evidence for potential court proceedings.

Consider compulsory licensing and public-health rules when developing market-entry strategies.

13. Conclusion

Biotechnology patent litigation in Russia is an important part of the country's intellectual property and pharmaceutical regulatory framework.

Part IV of the Russian Civil Code provides the principal legal foundation for protecting biotechnology inventions. Articles 1349, 1350, 1354, 1358, 1362 and 1398 are particularly important in determining patentability, infringement, compulsory licensing and patent invalidity.

The Nativa–Celgene lenalidomide dispute and the Sugen–Pharmacia–Nativa sunitinib litigation demonstrate how Russian courts approach pharmaceutical patent exclusivity, dependent inventions and compulsory licensing.

The SIP-863/2023 proceedings further illustrate the importance of scientific evidence and industrial applicability in pharmaceutical patent disputes.

Ultimately, Russian biotechnology patent litigation seeks to reconcile three major objectives:

Protection of scientific innovation and inventors' rights.

Prevention of unauthorized commercial exploitation of patented technologies.

Promotion of public health and lawful access to essential medicines.

The development of biological medicines, genetic engineering, recombinant DNA technology, gene editing and advanced pharmaceutical research will continue to create complex legal questions concerning patent ownership, scientific proof, infringement and compulsory licensing.

14. Important legal references and research materials

ReferenceLegal significance
Civil Code, Article 1349Excluded patent subject matter
Civil Code, Article 1350Patentability
Civil Code, Article 1354Scope of patent protection
Civil Code, Article 1356Inventorship
Civil Code, Article 1358Patent infringement
Civil Code, Article 1362Compulsory licensing
Civil Code, Article 1398Patent invalidity
Case A40-71471/2017Nativa–Celgene
Case A40-166505/2017Sugen–Pharmacia–Nativa
Case SIP-863/2023Industrial applicability of pharmaceutical compositions
Government Order No. 3718-r (2020)Remdesivir compulsory use

Primary and secondary research sources

Rospatent – Civil Code of the Russian Federation, Part IV.

Russian Civil Code – consolidated English text.

Nativa v. Celgene – Case A40-71471/2017.

Conflicting and dependent patents in Russia.

SIP-863/2023 – Pharmaceutical patent decision.

Practical Guide to Intellectual Property Litigation in Russia.

AIPM – Russian pharmaceutical patent litigation developments.

Academic qualification: The cited lenalidomide and sunitinib cases concern pharmaceutical patent disputes, not exclusively biological inventions. They are relevant comparative precedents for biotechnology patent litigation, but should not be misrepresented as direct judgments on gene-editing, DNA-sequence or recombinant-organism patents.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT